Aquestive Therapeutics, Inc.
Aquestive Therapeutics, Inc. (Nasdaq: AQST) develops pharmaceutical products and delivery technologies, including oral films intended as alternatives to invasive or inconvenient therapies. Its PharmFilm platform delivers medicines buccally, sublingually or on the tongue, while its AdrenaVerse platform develops… From the company’s description.
Over the twelve months to Sep 30, 2026, Aquestive Therapeutics, Inc. reported revenue of $48.84M, up 12.5% from a year earlier, and a net loss of $79.28M. Its operating margin was −114.1%, and operations used $39.76M in cash. In fiscal 2025, it reported revenue of $44.55M, down 22.6% from fiscal 2024, and a net loss of $83.78M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Aquestive Therapeutics, Inc. does
In the company’s own words
Aquestive Therapeutics, Inc. (Nasdaq: AQST) develops pharmaceutical products and delivery technologies, including oral films intended as alternatives to invasive or inconvenient therapies. Its PharmFilm platform delivers medicines buccally, sublingually or on the tongue, while its AdrenaVerse platform develops epinephrine prodrug candidates. The pipeline includes Anaphylm, a sublingual film candidate for severe allergic reactions, and AQST-108, a topical gel candidate being developed for potential treatment of alopecia areata. Aquestive also collaborates with pharmaceutical companies on drug development and manufactures licensed products marketed by licensees. Its licensed portfolio includes Suboxone for opioid dependence, Emylif for ALS, Ondif for nausea and vomiting, and Sympazan for seizures; Libervant is a buccal film for seizure clusters, with U.S. market access subject to regulatory restrictions. The company operates as a single reportable segment. Licensed products generated $44.5 million in revenue in 2025. Aquestive’s production facilities are in Indiana, and it has research laboratory facilities in New Jersey. Its website is https://www.aquestive.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- WARREN, NJ
- Fiscal year end
- December
- CIK
- 1398733
- SIC
- 2834
Financial performance, year by year
Fiscal 2018–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Aquestive Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Aquestive Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Aquestive Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Aquestive Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Aquestive Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”